Disc Medicine, Inc. (IRON)
(Delayed Data from NSDQ)
$29.79 USD
+0.79 (2.72%)
Updated May 3, 2024 04:00 PM ET
After-Market: $29.77 -0.02 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Disc Medicine, Inc. (IRON) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$57.11 | $85.00 | $40.00 | 96.93% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Disc Medicine, Inc. comes to $57.11. The forecasts range from a low of $40.00 to a high of $85.00. The average price target represents an increase of 96.93% from the last closing price of $29.00.
Analyst Price Targets (9 )
Broker Rating
Disc Medicine, Inc. currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, seven are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 77.78% and 11.11% of all recommendations. A month ago, Strong Buy made up 77.78%, while Buy represented 11.11%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 8 | 8 |
Buy | 1 | 1 | 1 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.33 | 1.22 | 1.22 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/2/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
4/1/2024 | Raymond James | Danielle Brill | Strong Buy | Moderate Buy |
3/22/2024 | H.C. Wainwright & Co. | Douglas Tsao | Strong Buy | Strong Buy |
3/21/2024 | Wedbush Securities | David M Nierengarten | Strong Buy | Strong Buy |
3/1/2024 | LifeSci Capital | Rami Katkhuda | Strong Buy | Strong Buy |
12/20/2023 | Cantor Fitzgerald & Co | Kristen Kluska | Strong Buy | Strong Buy |
10/22/2023 | SVB Securities | Thomas J Smith | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 9 |
Average Target Price | $57.11 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 78 of 252 |
Current Quarter EPS Est: | -1.00 |